Recruiting EARLY_PHASE1 INTERVENTIONAL 2-arm NCT06507657

Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

Sponsor: University of Minnesota

Conditions Cardiovascular Diseases Hypertension

Interventions Placebo tablet empagliflozin

Updated 4 times since 2024 Last updated: Oct 1, 2025 Started: Dec 12, 2024 Primary completion: Jan 15, 2029 Completion: Jan 15, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Cardiovascular Diseases and Hypertension and is currently actively recruiting participants. University of Minnesota leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

4 versions recorded

Nov 2025 — Present [monthly]

Recruiting EARLY_PHASE1
Nov 2024 — Nov 2025 [monthly]

Recruiting EARLY_PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Minnesota

Data source: University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States